Baird R W lowered shares of Bio-Techne (NASDAQ:TECH – Free Report) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports. Several other research ...

Bio-Techne (NASDAQ:TECH – Get Free Report) was downgraded by stock analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, Ratings reports. They ...

Bio-Techne (TECH) announced the launch of an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology ...

Fintel reports that on February 19, 2025, Baird downgraded their outlook for Bio-Techne (NasdaqGS:TECH) from Outperform to ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Baird analyst Catherine Ramsey Schulte downgraded Bio-Techne (TECH) to Neutral from Outperform with a price target of $68, down from $88. The ...

Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a leading provider of life sciences solutions ...

Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral ...

One of the standouts of today's morning trading session has been Bio-Techne, which logged a -1.7% drop and underperformed the S&P 500 by -2.0%. The Biotechnology stock is now trading at $73.33 per ...